1. Home
  2. PSFE vs MPLT Comparison

PSFE vs MPLT Comparison

Compare PSFE & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysafe Limited

PSFE

Paysafe Limited

HOLD

Current Price

$8.21

Market Cap

599.1M

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc. Common Stock

N/A

Current Price

$18.10

Market Cap

594.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSFE
MPLT
Founded
1996
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
599.1M
594.8M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
PSFE
MPLT
Price
$8.21
$18.10
Analyst Decision
Hold
Strong Buy
Analyst Count
5
4
Target Price
$10.60
$31.00
AVG Volume (30 Days)
795.2K
265.5K
Earning Date
11-13-2025
12-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,683,103,000.00
N/A
Revenue This Year
$1.95
N/A
Revenue Next Year
$6.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.43
$12.24
52 Week High
$24.11
$20.86

Technical Indicators

Market Signals
Indicator
PSFE
MPLT
Relative Strength Index (RSI) 42.60 N/A
Support Level $7.39 N/A
Resistance Level $8.29 N/A
Average True Range (ATR) 0.41 0.00
MACD 0.27 0.00
Stochastic Oscillator 87.25 0.00

Price Performance

Historical Comparison
PSFE
MPLT

About PSFE Paysafe Limited

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

About MPLT MapLight Therapeutics Inc. Common Stock

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Share on Social Networks: